Study on Acalabrutinib for Patients with Chronic Lymphocytic Leukemia (CLL) Who Cannot Tolerate Ibrutinib

Inclusion Criteria

• Must be 18 years or older.
• Have a prior diagnosis of Chronic Lymphocytic Leukemia (CLL).
• Have received at least one previous treatment for CLL.
• Cannot tolerate Ibrutinib due to side effects.
• Have documented disease progression after stopping Ibrutinib, according to specific medical criteria.
• Be willing and able to participate in all study evaluations and procedures, including swallowing capsules.
• Have a performance status score of 2 or less, indicating they are able to carry out all self-care but unable to carry out any work activities.

Exclusion Criteria

• Have ongoing side effects from Ibrutinib.
• Have received any other cancer treatment for CLL between stopping Ibrutinib and starting this study.
• Have previously used a BCL-2 inhibitor like Venetoclax.
• Have had another type of cancer in the past, unless it was treated and has been in remission for at least 2 years.
• Have significant heart disease, such as uncontrolled heart rhythm problems or recent heart attack.
• Have digestive issues that affect the absorption of medication.
• Have evidence of disease progression on Ibrutinib or any BTK inhibitor.
• Have CLL that has spread to the central nervous system.
• Have active infections like HIV or hepatitis B or C.
• Have uncontrolled autoimmune blood disorders.
• Have had a stroke or brain bleed in the past 2 months.
• Have a history of bleeding disorders.
• Have had a stomach ulcer diagnosed recently.
• Have had major surgery within the last 28 days.
• Require treatment with certain medications that interact with the study drug.